A life-saving meningococcal vaccine covering all five common strains of the deadly disease could soon be available thanks to ...

ACIP recommends pentavalent meningococcal vaccine Penmenvy (meningococcal Groups A, B, C, W, and Y vaccine) for individuals 10 through 25 years of age.

Also active in the category is Sanofi, which sells MenACWY vaccines Menactra and MenQuadfi, lacking coverage of the B serogroup considered the most common cause of meningococcal disease in the US.

Meningococcal vaccination is vital for teens to prevent serious infections like meningitis and ensure long-term protection.

This recommendation, if adopted, will allow for vaccination against serogroups A, B, C, W, and Y in fewer doses, could simplify meningococcal vaccination delivery and could improve immunization ...

Meningococcal disease is uncommon, but can quickly become life-threatening if the bacterial infection gets into the bloodstream or the membranes that line the spinal cord and brain.

GSK’s five-in-one meningococcal vaccine has been recommended by the US Centers for Disease Control and Prevention’s (CDC) immunisation panel as part of the adolescent meningococcal vaccination ...

The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in ...

The ACIP voted that Penmenvy may be used as part of the adolescent meningococcal vaccination schedule as an alternative to separate administration of MenACWY and MenB. The Centers for Disease ...